Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 2, 2000, Pages 93-100

  Vaidyanathan, S ^a   Boroujerdi, M ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Blood cells; Dexrazoxane; Doxorubicin; Hemoglobin; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 14; DOXORUBICIN; HEMOGLOBIN; MESSENGER RNA; RAZOXANE; TRANSFERRIN RECEPTOR;

ARTICLE; BLOOD CELL; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; ERYTHROCYTE; ERYTHROCYTE GHOST; HEART PROTECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0033885180     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000122     Document Type: Article

References (21)

1. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs
2. The production of hydroxyl radicals by Adriamycin in red blood cells
3. Comparative study of the pharmacokinetics and toxicity of high dose epirubicin with or without dexrazoxane in patients with advanced malignancy
4. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane
5. Ferritin and ceruloplasmin in oxidative damage: Review and recent findings
6. Modulation of glutathione and glutathione dependent antioxidant enzymes in the mouse heart following doxorubicin therapy
7. Lipid peroxidation and possible hydroxyl radical formation stimulated by the self-reduction of a doxorubicin-iron (III complex
8. The interaction of the cardioprotective agent ICRF-187 (of (+)- 1,2-bis-(3,5-dioxopipcrazin-1-yl)propane); its hydrolysis product (ICRF-189); and other chelating agents with Fe(III) and Cu(II) complexes of Adriamycin
9. The iron (III) and copper (II) complexes of Adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 (of (+)-1,2-bis-(3,5-dioxopiperazin-1-yl)propane)
10. Chemical, biological and clinical aspects of dexrazoxane and other his dioxopiperazines
11. Pharmacokinetics of cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin
12. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide
13. The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-flurouracil and tamoxifen in metastatic breast cancer patients
14. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction
15. Oxidative destruction of erythrocyte ghost membranes catalyzed by a doxorubicin-iron complex
16. Mechanisms of anthracycline cardiotoxicity: Are metabolites involved?
17. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
18. Pharmacokinetic-toxicodynamic relationships of Adriamycin in rats: Prediction of butylated hydroxyanisole-mediated reduction in anthracycline cardiotoxicity
19. Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein
20. Dexrazoxanc (ICR-187)